


1/33




1-(Propoxymethyl)- maleimide

MIRA-1

Fig. 1A

2/33



2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one

PRIMA-1

Fig. 1B




Fig. 2A




Fig. 2A
CONTINUATION




Fig. 2B

6/33




Fig. 2B
CONTINUATION

7/33





Fig. 2C

8/33

Saos-2-His-273



days after treatment

Fig. 2C
CONTINUATION

9/33




Fig. 2D

10/33




Fig. 2D
CONTINUATION

11/33




Fig. 3A

12/33




Fig. 3B

13/33




Fig. 3C

14/33




Fig. 3C
CONTINUATION

15/33




Fig. 4A

16/33





Fig. 4A
CONTINUATION

17/33



18/33

GSTI-wtp53

PAb 240




Fig. 4B




Fig. 4B
CONTINUATION

20/33




Fig. 4C

21/33

GST-mtp53-248




Fig. 4C
CONTINUATION

22/33




Fig. 5

23/33




Fig. 6A

24/33




Fig. 6B




Fig. 7

26/33




Fig. 8

27/33




Fig. 9A

28/33




Fig. 9B

29/33






Fig. 9C

30/33

A



B



C




Fig.10

31/33




Fig. 11




Fig. 12A

PRIMA-1




Fig. 12B